Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 167Rituximab 159Specimen Handling 115Biopsy 91Magnetic Resonance Spectroscopy 89Vincristine 84Doxorubicin 78Prednisone 75fludarabine 70venetoclax 67obinutuzumab 62Dexamethasone 55ibrutinib 54Lenalidomide 54Cytarabine 48Methotrexate 47acalabrutinib 43Etoposide 41CT-P10 41blinatumomab 38fludarabine phosphate 35Gemcitabine 33Bendamustine Hydrochloride 33zanubrutinib 30pembrolizumab 30glofitamab 30Calcium Dobesilate 30prednylidene 29deltacortene 28Nivolumab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
efineptakin alfa × Lymphoid × 90 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡